BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 35730438)

  • 21. 7,8-dihydroxyflavone Ameliorates Motor Deficits Via Suppressing α-synuclein Expression and Oxidative Stress in the MPTP-induced Mouse Model of Parkinson's Disease.
    Li XH; Dai CF; Chen L; Zhou WT; Han HL; Dong ZF
    CNS Neurosci Ther; 2016 Jul; 22(7):617-24. PubMed ID: 27079181
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Curcumin Inhibits Lipopolysaccharide-Induced Mucin 5AC Hypersecretion and Airway Inflammation via Nuclear Factor Erythroid 2-Related Factor 2.
    Lin XP; Xue C; Zhang JM; Wu WJ; Chen XY; Zeng YM
    Chin Med J (Engl); 2018 Jul; 131(14):1686-1693. PubMed ID: 29998888
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mulberry fruit ameliorates Parkinson's-disease-related pathology by reducing α-synuclein and ubiquitin levels in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/probenecid model.
    Gu PS; Moon M; Choi JG; Oh MS
    J Nutr Biochem; 2017 Jan; 39():15-21. PubMed ID: 27741433
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Further characterisation of the LPS model of Parkinson's disease: a comparison of intra-nigral and intra-striatal lipopolysaccharide administration on motor function, microgliosis and nigrostriatal neurodegeneration in the rat.
    Hoban DB; Connaughton E; Connaughton C; Hogan G; Thornton C; Mulcahy P; Moloney TC; Dowd E
    Brain Behav Immun; 2013 Jan; 27(1):91-100. PubMed ID: 23044176
    [TBL] [Abstract][Full Text] [Related]  

  • 25. DL‑3‑n‑butylphthalide reduces microglial activation in lipopolysaccharide‑induced Parkinson's disease model mice.
    Chen Y; Jiang M; Li L; Ye M; Yu M; Zhang L; Ge B; Xu W; Wei D
    Mol Med Rep; 2018 Mar; 17(3):3884-3890. PubMed ID: 29286148
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Characterization of the lipopolysaccharide induced model of Parkinson's disease: Role of oxidative stress and neuroinflammation.
    Sharma N; Nehru B
    Neurochem Int; 2015 Aug; 87():92-105. PubMed ID: 26055970
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Development of An Oral Treatment with the PPAR-γ-Acting Cannabinoid VCE-003.2 Against the Inflammation-Driven Neuronal Deterioration in Experimental Parkinson's Disease.
    Burgaz S; García C; Gómez-Cañas M; Muñoz E; Fernández-Ruiz J
    Molecules; 2019 Jul; 24(15):. PubMed ID: 31349553
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Anti-inflammatory and neuroprotective effects of an orally active apocynin derivative in pre-clinical models of Parkinson's disease.
    Ghosh A; Kanthasamy A; Joseph J; Anantharam V; Srivastava P; Dranka BP; Kalyanaraman B; Kanthasamy AG
    J Neuroinflammation; 2012 Oct; 9():241. PubMed ID: 23092448
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Neuroprotective effects of Astilbin on MPTP-induced Parkinson's disease mice: Glial reaction, α-synuclein expression and oxidative stress.
    Zhu YL; Sun MF; Jia XB; Cheng K; Xu YD; Zhou ZL; Zhang PH; Qiao CM; Cui C; Chen X; Yang XS; Shen YQ
    Int Immunopharmacol; 2019 Jan; 66():19-27. PubMed ID: 30419450
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Nanostructure lipid carriers enhance alpha-mangostin neuroprotective efficacy in mice with rotenone-induced neurodegeneration.
    Sakamula R; Yata T; Thong-Asa W
    Metab Brain Dis; 2022 Jun; 37(5):1465-1476. PubMed ID: 35353275
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intranasal Exposure to Low-Dose Rotenone Induced Alpha-Synuclein Accumulation and Parkinson's Like Symptoms Without Loss of Dopaminergic Neurons.
    Sharma M; Kaur J; Rakshe S; Sharma N; Khunt D; Khairnar A
    Neurotox Res; 2022 Feb; 40(1):215-229. PubMed ID: 34817799
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Progression of intestinal permeability changes and alpha-synuclein expression in a mouse model of Parkinson's disease.
    Kelly LP; Carvey PM; Keshavarzian A; Shannon KM; Shaikh M; Bakay RA; Kordower JH
    Mov Disord; 2014 Jul; 29(8):999-1009. PubMed ID: 24898698
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dopaminergic neuroprotection and regeneration by neurturin assessed by using behavioral, biochemical and histochemical measurements in a model of progressive Parkinson's disease.
    Oiwa Y; Yoshimura R; Nakai K; Itakura T
    Brain Res; 2002 Aug; 947(2):271-83. PubMed ID: 12176170
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Apocyanin, a Microglial NADPH Oxidase Inhibitor Prevents Dopaminergic Neuronal Degeneration in Lipopolysaccharide-Induced Parkinson's Disease Model.
    Sharma N; Nehru B
    Mol Neurobiol; 2016 Jul; 53(5):3326-3337. PubMed ID: 26081143
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dose-related biphasic effect of the Parkinson's disease neurotoxin MPTP, on the spread, accumulation, and toxicity of α-synuclein.
    Merghani MM; Ardah MT; Al Shamsi M; Kitada T; Haque ME
    Neurotoxicology; 2021 May; 84():41-52. PubMed ID: 33549656
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Erinacine A Prevents Lipopolysaccharide-Mediated Glial Cell Activation to Protect Dopaminergic Neurons against Inflammatory Factor-Induced Cell Death In Vitro and In Vivo.
    Lee SL; Hsu JY; Chen TC; Huang CC; Wu TY; Chin TY
    Int J Mol Sci; 2022 Jan; 23(2):. PubMed ID: 35054997
    [No Abstract]   [Full Text] [Related]  

  • 37. Treadmill exercise produces neuroprotective effects in a murine model of Parkinson's disease by regulating the TLR2/MyD88/NF-κB signaling pathway.
    Koo JH; Jang YC; Hwang DJ; Um HS; Lee NH; Jung JH; Cho JY
    Neuroscience; 2017 Jul; 356():102-113. PubMed ID: 28527958
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ablation of tau causes an olfactory deficit in a murine model of Parkinson's disease.
    Beauchamp LC; Chan J; Hung LW; Padman BS; Vella LJ; Liu XM; Coleman B; Bush AI; Lazarou M; Hill AF; Jacobson L; Barnham KJ
    Acta Neuropathol Commun; 2018 Jul; 6(1):57. PubMed ID: 29976255
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mechanistic insights into the anti-depressant effect of curcumin based on network pharmacology and experimental validation.
    Guo J; Fang M; Xiong Z; Zhou K; Zeng P
    Naunyn Schmiedebergs Arch Pharmacol; 2024 Jan; 397(1):583-598. PubMed ID: 37490124
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Potentiation of methamphetamine neurotoxicity by intrastriatal lipopolysaccharide administration.
    Jung BD; Shin EJ; Nguyen XK; Jin CH; Bach JH; Park SJ; Nah SY; Wie MB; Bing G; Kim HC
    Neurochem Int; 2010 Jan; 56(2):229-44. PubMed ID: 19850096
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.